Johnson & Johnson (NYSE:JNJ) lifted its full-year sales forecast on Wednesday, signaling confidence in its underlying business despite ongoing concerns over potential U.S. tariffs on pharmaceutical imports. The news pushed shares up more than 5% intra-day today.
The healthcare giant now expects 2025 sales to range between $93.2 billion and $93.6 billion, up from its previous projection of $91 billion to $91.8 billion. The revision reflects stronger demand across its drug and medical device businesses.
While tariff risks remain, J&J has tempered its expectations for the financial impact. The company previously estimated a $400 million hit from potential U.S.–China trade measures, but following a recent framework trade agreement, that figure has likely been reduced to about $200 million. CFO Joseph Wolk noted it’s still too early to assess how tariffs might affect 2026 results.
For the second quarter, Johnson & Johnson reported adjusted earnings per share of $2.77, beating analyst estimates of $2.68. The results reflect continued resilience across its core segments, helping the company weather geopolitical uncertainties while maintaining strong profitability.
